Evidence map›Paper›PMID 35993278›Full record

ArticleBehavioral medicine (Washington, D.C.)

Facilitators of PrEP Persistence among Black and Latinx Transgender Women in a PrEP Demonstration Project in Southern California.

Erik D Storholm, Adedotun Ogunbajo, Carrie L Nacht, Chloe Opalo, Keith J Horvath, Phoebe Lyman, Risa Flynn, Cathy J Reback, Jill Blumenthal, David J Moore and 2 more

Open access · greenAbstract read
In one paragraph

Article in Behavioral medicine (Washington, D.C.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Erik D StorholmSchool of Public Health, San Diego State University.
Adedotun OgunbajoDepartment of Behavioral and Social Sciences, Brown University School of Public Health.ORCID 0000-0002-3074-6431
Carrie L NachtSchool of Public Health, San Diego State University.
Chloe OpaloLos Angeles LGBT Center.
Keith J HorvathDepartment of Psychology, San Diego State University.
Phoebe LymanLos Angeles LGBT Center.
Risa FlynnLos Angeles LGBT Center.
Cathy J RebackCenter for HIV Identification, Prevention and Treatment Services, Department of Family Medicine, University of California Los Angeles.
Jill BlumenthalAntiViral Research Center, University of California, San Diego School of Medicine.
David J MooreAntiViral Research Center, University of California, San Diego School of Medicine.
Robert BolanLos Angeles LGBT Center.
Sheldon MorrisAntiViral Research Center, University of California, San Diego School of Medicine.
Los Angeles LGBT Center · USUniversity of California San Diego · USSan Diego State University · USJohn Brown University · USRAND Corporation · USUniversity of California, Los Angeles · US

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SONIA JAIN · 1994 to 2026
$78.4M
UCLA Rapid, Relevant, Rigorous Implementation Science HubP30MH058107 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Nina Thawata Harawa · 1997 to 2026
$53.5M
Intimate Partner Violence and HIV Prevention among Sexual Minority MenR01MH126762 · NIMH · SAN DIEGO STATE UNIVERSITY · PI STORHOLM, ERIK D. · 2021 to 2025
$3.2M
Developing and testing a telehealth intervention to increase HIV pre-exposure prophylaxis uptake and adherence among sexual minority men in NigeriaK01MH129165 · NIMH · RAND CORPORATION · PI Adedotun Ogunbajo · 2022 to 2026
$980k
Risk and Protective Factors for Adherence to Pre-Exposure Prophylaxis (PrEP) in Transwomen of ColorR21DA044073 · NIDA · RAND CORPORATION · PI STORHOLM, ERIK D. · 2017 to 2018
$494k
NCATS NIH HHS UL1 TR001442NIAID NIH HHS P30 AI036214NIDA NIH HHS R21 DA044073NIMH NIH HHS K01 MH129165NIMH NIH HHS P30 MH058107NIMH NIH HHS R01 MH126762
6 · The paper itself

Abstract

Black and Latinx transgender women in the United States (U.S.) are at disproportionately high risk for HIV. Although HIV pre-exposure prophylaxis (PrEP) reduces the risk of HIV infection, uptake and persistence (i.e., ability to continue taking PrEP over time) can be a challenge for Black and Latinx transgender women due to myriad social and structural forces. In this qualitative study, we present unique data on the facilitators of PrEP persistence from Black and Latinx transgender women who initiated PrEP and exhibited varying levels of persistence during a demonstration project in Southern California. PrEP persistence was assessed by collecting quantitative intracellular tenofovir-diphosphate (TFV-DP) levels on dried blood spot (DBS) samples collected at weeks 12 and 48. Informed by the socioecological framework, we conducted and analyzed interviews using qualitative content analysis to determine themes on the facilitators of PrEP persistence. Individual-level facilitators included the use of reminders, having high individual-level HIV risk perception, feeling empowered to take PrEP, and reporting having improved peace of mind and mental health because of taking PrEP. Interpersonal/Community-level facilitators included feeling motivation to prevent HIV in the community, motivation to prevent HIV in the context of sex work, and having high community-level risk perception. Structural-level facilitators included having positive experiences in affirming healthcare settings and having PrEP visits combined with other gender-related healthcare visits. Interventions aiming to increase PrEP uptake and persistence among Black and Latinx transgender women in the U.S. should harness the multiple levels of support exhibited by those who were able to start and persist on PrEP in the face of the myriad social and structural barriers.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisTransgender PersonsBlack or African AmericanCaliforniaFemaleHispanic or LatinoHomosexuality, MaleHumansMaleUnited StatesAnti-HIV Agentshealth equityHIV preventionmedication adherencePrEP persistenceTransgender women

Identifiers

PMID35993278
PMCPMC9943802
OpenAlexW4292583043

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.